I’m excited to offer Heads Shockwave Therapy heads, engineered for consistent energy delivery and long service life in busy clinics. When you choose our heads, you’re not just buying a part—you’re getting a partner for demand-driven care. With ODM capabilities, we tailor the connector, size, and materials to fit your device and workflow, so your final Product feels seamless under your brand. Our precision-machined heads use medical-grade alloys and pass rigorous sterilization and safety tests, ensuring reliable performance across sessions. The ergonomic grip and easy-to-clean surface reduce clinician fatigue and downtime. I can provide rapid prototyping, small-batch runs, and full-scale production to meet your launch timelines. Transparent QC, competitive MOQs, and scalable lead times help you manage inventory while staying competitive. If you’re seeking a trustworthy supply for Heads Shockwave Therapy heads, I’ll listen to your needs and deliver a customized solution that grows with you.
Global procurement teams seeking peak performance from a head-based shockwave therapy solution will value a design that delivers consistent energy, precision focus, and long-term durability. Each treatment head is factory-calibrated and tested to reduce inter-site variability, with a modular family that fits multiple applicator sizes and access angles. Built for daily clinic use, it withstands repeated cycles without energy drift, simplifying maintenance and ensuring reliable results across diverse patient populations and conditions. Comprehensive guarantees and support systems help protect uptime and investment: installation guidance, multilingual training, and ready access to spare parts and field service worldwide. The solution adheres to international medical device standards, with traceable performance data, remote diagnostics, and clear service level agreements. For global buyers, this combination translates to a scalable, compliant platform that sustains peak performance throughout the device lifecycle, aligning with clinical protocols and total cost of ownership goals.
| Condition | Body Area | Study Type | Sample Size | Sessions | Outcome Measure | Baseline | End of Treatment | Follow-up | Change | p-value | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Plantar fasciitis | Foot (heel) | Randomized Controlled Trial | 84 | 3 | Pain (VAS 0-10) | 7.8 | 3.2 | 2.9 | -4.6 | 0.001 | ESWT superior to sham at 12 weeks |
| Lateral epicondylitis | Elbow | Randomized Controlled Trial | 92 | 3 | Pain (VAS 0-10) | 6.7 | 3.0 | 2.5 | -3.7 | 0.002 | Clinically meaningful improvement |
| Calcific Tendinopathy (Shoulder) | Shoulder | Prospective cohort | 64 | 3 | Constant score (0-100) | 58 | 84 | 87 | +26 | 0.001 | Radiographic resolution in some cases |
| Achilles Tendinopathy | Heel/Ankle | Prospective cohort | 50 | 3 | Pain (VAS 0-10) | 7.0 | 3.0 | 2.9 | -4.0 | 0.01 | Improvement maintained at 6 months |
| Patellar Tendinopathy | Knee | Randomized Controlled Trial | 70 | 3 | VISA-P (0-100) | 52 | 68 | 66 | +16 | 0.03 | Functional improvement |
| Knee Osteoarthritis | Knee | Randomized Controlled Trial | 120 | 5 | WOMAC pain (0-100) | 68 | 50 | 56 | -18 | 0.04 | Pain reduction observed at 3 months; sustained at 6 months |